Caribou Biosciences Shuts Down After Failing to Secure Trial Funding
Biotech firm Caribou Biosciences is closing after failing to raise funds for a late-stage trial of its CRISPR-based CAR-T therapy for lymphoma.
FTMQ Health, written by our newsroom0 views

Caribou Biosciences is shutting down after failing to raise the money needed to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma, STAT News reported on Tuesday. The Berkeley, California, biotech firm is discontinuing the clinical development of its two CRISPR-based CAR-T therapies, including vispa-cel for treating advanced B-cell non-Hodgkin lymphoma. [1]
STAT News reported that over the past year, Caribou Biosciences had worked successfully with the Food and Drug Administration to finalize plans for its research. The company was founded in 2011 in Berkeley, California, as a biopharmaceutical firm focused on advancing CRISPR-based genome editing for therapeutic use. Biochemist and structural biologist Rachel Haurwitz co-founded the company and served as its chief executive officer and president. [1][2][4]
Caribou Biosciences was borne from the research lab of CRISPR scientist Jennifer Doudna, STAT News reported. Doudna is a biochemist who serves as the Li Ka Shing Chancellor's Chair Professor at the University of California, Berkeley, and has been an investigator with the Howard Hughes Medical Institute since 1997. She received the 2020 Nobel Prize in Chemistry alongside Emmanuelle Charpentier for developing a method for genome editing. [1][3]
The company developed next-generation CAR-T therapies that are allogeneic, meaning they are off-the-shelf products. These treatments offer potential advantages over autologous approaches by improving scalability, reducing manufacturing time, and enabling broader patient access. Its technology platform uses hybrid RNA-DNA guide molecules to enhance editing specificity and reduce off-target effects in engineered cell therapies. [1][4]
In short
- Caribou Biosciences is shutting down after failing to raise funds for a late-stage lymphoma therapy trial.
- The company will discontinue clinical development of its two CRISPR-based CAR-T therapies, including vispa-cel.
- Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna and chief executive officer Rachel Haurwitz.
- The firm worked with the Food and Drug Administration over the past year to finalize trial plans.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting downSTAT News, 45d ago (the report this story comes from)
Background
- [2]Rachel Haurwitz on Wikipedia
- [3]Jennifer Doudna on Wikipedia
- [4]Caribou Biosciences on Grokipedia
- [5]Jennifer Doudna on Grokipedia
Our newsroom writes these reports with the help of software, from the 5 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Phase III breast cancer study tests reduced post surgery therapyMedical Science, 24d ago
More in Top Stories
- United Therapeutics performs first UThymoKidney transplant in EXTEND trial16h ago
- Princeton neuroscience researcher detained by ICE following conference16h ago
- FDA rejects Capricor Therapeutics Duchenne muscular dystrophy cell therapy16h ago
- Northern Ireland ambulance service misses two-hour target over 2,000 times1d ago
- Senior surgeon calls for police investigation into Scottish hospital patient deaths1d ago
- Malaria antibody prevents infection in infants but interferes with vaccine1d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.